Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aran F Labrijn

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Current Opinion in Immunology|June 26, 2008
When binding is enough: nonactivating antibody formatsAran F Labrijn, Rob C Aalberse, Janine Schuurman
Science (New York, N.Y.)|November 16, 2016
Hitting Ebola, to the power of twoAran F Labrijn, Paul W H I Parren
Mabs|September 8, 2012
Fab-arm exchange: what's in a name?Janine Schuurman, Aran F Labrijn, Paul W H I Parren
Cancers|January 20, 2021
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid TumorsJim Middelburg, Kristel Kemper, Patrick Engelberts, et al.
Nature Reviews. Drug Discovery|June 9, 2019
Bispecific antibodies: a mechanistic review of the pipelineAran F Labrijn, Maarten L Janmaat, Janice M Reichert, et al.
Mabs|May 3, 2014
Opening the door to innovationJanine Schuurman, Yvo F Graus, Aran F Labrijn, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 22, 2024
Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen bindingNikolaus Frischauf, Jürgen Strasser, Ellen G F Borg, et al.
Immunology and Cell Biology|March 30, 2023
Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activityAlicia M Chenoweth, Sandra Esparon, Bruce D Wines, et al.
Frontiers in Immunology|January 23, 2024
Impact of structural modifications of IgG antibodies on effector functionsTimon Damelang, Maximilian Brinkhaus, Thijs L J van Osch, et al.
Small Science|July 16, 2025
A Kinetic Model of Antigen-Dependent IgG Oligomerization and Complement BindingJürgen Strasser, Nikolaus Frischauf, Lukas Schustereder, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Current Opinion in Immunology|June 26, 2008
When binding is enough: nonactivating antibody formatsAran F Labrijn, Rob C Aalberse, Janine Schuurman
Science (New York, N.Y.)|November 16, 2016
Hitting Ebola, to the power of twoAran F Labrijn, Paul W H I Parren
Mabs|September 8, 2012
Fab-arm exchange: what's in a name?Janine Schuurman, Aran F Labrijn, Paul W H I Parren
Cancers|January 20, 2021
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid TumorsJim Middelburg, Kristel Kemper, Patrick Engelberts, et al.
Nature Reviews. Drug Discovery|June 9, 2019
Bispecific antibodies: a mechanistic review of the pipelineAran F Labrijn, Maarten L Janmaat, Janice M Reichert, et al.
Mabs|May 3, 2014
Opening the door to innovationJanine Schuurman, Yvo F Graus, Aran F Labrijn, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 22, 2024
Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen bindingNikolaus Frischauf, Jürgen Strasser, Ellen G F Borg, et al.
Immunology and Cell Biology|March 30, 2023
Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activityAlicia M Chenoweth, Sandra Esparon, Bruce D Wines, et al.
Frontiers in Immunology|January 23, 2024
Impact of structural modifications of IgG antibodies on effector functionsTimon Damelang, Maximilian Brinkhaus, Thijs L J van Osch, et al.
Small Science|July 16, 2025
A Kinetic Model of Antigen-Dependent IgG Oligomerization and Complement BindingJürgen Strasser, Nikolaus Frischauf, Lukas Schustereder, et al.
Pageof 4